کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
9394040 1283968 2005 11 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Evaluation of Therapy for Lymphoma
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی رادیولوژی و تصویربرداری
پیش نمایش صفحه اول مقاله
Evaluation of Therapy for Lymphoma
چکیده انگلیسی
Positron emission tomography (PET) using 18F-fluorodeoxyglucose (18F-FDG) is the best noninvasive imaging technique for to assess response in patients suffering from lymphoma. Early response evaluation (“interim PET”) after one, a few cycles, or at midtreatment can predict response, progression-free survival, and overall survival. We calculated from data of 7 studies an overall sensitivity to predict treatment failure of 79%, a specificity of 92%, a positive predictive value (PPV) of 90%, a negative predictive value (NPV) of 81%, and an accuracy of 85%. Although it is not yet indicated to change patient management based on residual 18F-FDG uptake on interim scan in chemotherapy-sensitive patients, prospective studies evaluating the role of an interim PET in patient management clearly are warranted. 18F-FDG PET also has an important prognostic role in relapsing patients after reinduction chemotherapy before high-dose chemotherapy (HCT) followed by autologous stem cell transplantation (ASCT). However, all chemotherapy-sensitive patients remain candidates for HCT followed by ASCT, even if 18F-FDG PET showed residual 18F-FDG uptake. We calculated from data of 3 studies an overestimated risk of relapse in 16% of all PET-positive patients. Some patients with residual 18F-FDG uptake will have a good outcome after HCT followed by ASCT. 18F-FDG PET is the imaging technique of choice for end-of-treatment evaluation. However, 18F-FDG is not specific for tumoral tissue. Active inflammatory lesions and infectious processes can be falsely interpreted as malignant residual cells. However, a negative 18F-FDG PET cannot exclude minimal residual disease. Consequently, it is always indicated to correlate PET findings with clinical data, other imaging modalities, and/or a biopsy. We calculated, from data of 17 studies in end-of-treatment evaluation, a sensitivity of 76%, a specificity of 94%, a PPV of 82%, a NPV 92%, and an accuracy of 89%.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Seminars in Nuclear Medicine - Volume 35, Issue 3, July 2005, Pages 186-196
نویسندگان
, , , , , , , ,